25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1α-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 100, Issue 4-5, 2006, Pages 184-192

  de Lyra, Eduardo Carneiro ^a   da Silva, Iran Amorim ^b   Katayama, Maria Lucia Hirata ^c   Brentani, Maria Mitzi ^c   Nonogaki, Sueli ^d   Góes, João Carlos Sampaio ^a   Folgueira, Maria Aparecida Azevedo Koike ^c  

^a Instituto Brasileiro de Controle do Cancer   (Brazil)

^b Disciplina de Urologia   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

1 Hydroxylase; 1,25(OH)2D3; 24 Hydroxylase; 25(OH)D3; Breast cancer; Vitamin D receptor (VDR)

Indexed keywords

25 DIHYDROXYVITAMIN D3; CALCITRIOL; OXYGENASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL RECEPTOR; STEROID MONOOXYGENASE; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BREAST CANCER; BREAST RECONSTRUCTION; BREAST TUMOR; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITAMIN BLOOD LEVEL; BLOOD; BRAZIL; BREAST; CYTOLOGY; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ANIMALIA;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAZIL; BREAST; BREAST NEOPLASMS; CALCIFEDIOL; CALCITRIOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTORS, CALCITRIOL; REGRESSION ANALYSIS; STEROID HYDROXYLASES;

EID: 33746822914     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.04.009     Document Type: Article

References (41)

1. 3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J. Steroid Biochem. Mol. Biol. 83 1-5 (2002) 85-92
2. 3 receptor (VDR) expression in HC-11 mammary cell: regulation by growth-modulatory agents, differentiation, and Há-ras transformation. Breast Cancer Res. Treat. 54 2 (1999) 123-133
3. Katayama M.L.H., Pasini F.S., Folgueira M.A.A.K., Snitcovsky I.M.L., and Brentani M.M. Molecular targets of 1,25(OH)2D3 in HC11 normal mouse mammary cell line. J. Steroid Biochem. Mol. Biol. 84 1 (2003) 57-69
4. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res. 60 10 (2000) 2673-2679
5. Erben R.G., Soegiarto D.W., Weber K., Zeitz U., Lieberherr M., Gniadecki R., Möller G., Adamski J., and Balling R. Deletion of deoxyribonuclec acid binding domain of the Vitamin D receptor abrogates genomic and nongenomic functions of Vitamin D. Mol. Endocrinol. 16 7 (2002) 1524-1537
6. Mehta R.G., and Mehta R.R. Vitamin D and Cancer. J. Nutr. Biochem. 13 5 (2002) 252-264
7. Friedrich M., Heinsen C.V., Tilgen W., Schmidt W., Reichrath J., and Axt-Fliedner R. Vitamin D receptor(VDR) expression is not a prognostic factor in breast cancer. Anticancer Res. 22 3 (2002) 1919-1924
8. Eisman J.A., Suva L.J., and Martin T.J. Significance of 1,25 dihydroxy Vitamin D3 receptor in primary breast cancer. Cancer Res. 46 10 (1986) 5406-5408
9. Friedrich M., Rafi L., Tilgen W., Schmidt W., and Reichrath J. Expression of 1,25-dihydroxy Vitamin D3 recptor in breast carcinoma. J. Histochem. Cytochem. 46 11 (1998) 1335-1337
10. Friedrich .M., Axt-Fliedner R., Heinsen C.V., Tilgen W., Schmidt W., and Reichrath J. Analysis of Vitamin D-recptor (VDR) and retinoid X-receptor α in breast cancer. Histochem. J. 34 1-2 (2002) 35-40
11. 3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture. Virchows Arch. 444 2 (2004) 175-182
12. Gorham E.D., Garland F.C., and Garland C.F. Sunlight and breast cancer incidence in the URRS. Int. J. Epidemiol. 19 4 (1990) 820-824
13. Garland F.C., Garland C.F., Gorham E.D., and Young J.F. Geographic variation in breast câncer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 19 6 (1990) 614-622
14. Ainsleigh H.G. Beneficial effects of sun exposure on cancer mortality. Prev. Med. 22 1 (1993) 132-140
15. Janowsky E.C., Lester G.E., Weinberg C.R., Millikan R.C., Schildkraut J.M., Garret P.A., and Hulka B.S. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 2 3 (1999) 283-291
16. Mawer E.B., Walls J., Howell A., Davies M., Ratcliffe W.A., and Bundred N.J. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J. Clin. Endocrinol. Metab. 82 1 (1997) 118-122
17. Colston K.W., Berger U., and Coombes R.C. Possible role for Vitamin D in controlling breast cancer cell proliferation. Lancet 28 1 (1989) 188-191
18. Mehta R.G., Hussain E.A., Mehta R.R., and Das Gupta T.K. Chemoprevention of mammary carcinogenesis by 1 alphahydroxyvitamin D5, a synthetic analog of Vitamin D. Mutat. Res. 523-524 (2003) 253-264
19. Brenza H.L., and DeLuca H.F. Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expresión by parathyroid hormone and 1,25-dihydroxyvitamin D3. Arch. Biochem. Biophys. 381 1 (2000) 143-152
20. 3 suppresses growth and induces differention in an autocrine fashion. Mol. Cancer Res. 1 1 (2002) 56-67
21. 3-induced growth inhibition. Cancer Res. 61 7 (2001) 2852-2856
22. 3 by a human small cell lung cancer cell line. J. Clin. Endocrinol. Metab. 79 2 (1994) 554-560
23. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., and Holick M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 7 5 (1998) 391-395
24. Holick M.F., Kleiner-Bossaller A., Schnoes H.K., Kasten P.M., Boyle I.T., and DeLuca H.F. 1,24,25-Trihydroxyvitamin D3. A metabolite of Vitamin D3 effective on intestine. J. Biol. Chem. 248 19 (1973) 6691-6696
25. Wang Y.Z., Li H., Bruns M.E., Uskokovic M., Truitt G.A., Horst R., Reinhardt T., and Christakos S. Effect of 1,25,28-trihydroxyvitamin D2 and 1,24,25-trihydroxyvitamin D3 on intestinal calbindin-D9K mRNA and protein: is there a correlation with intestinal calcium transport?. J. Bone Miner. Res. 8 12 (1993) 1483-1490
26. Nishimura A., Shinki T., Jin C.H., Ohyama Y., Noshiro M., Okuda K., and Suda T. Regulation messenger ribonucleic acid expression of 1 alpha,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts. Endocrinology 134 4 (1994) 1794-1799
27. Dwivedi P.P., Onndahl J.L., Kola I., Hume D.A., and May B.K. Regulation of rat cytochrome P450 (CYP24) gene expression. Evidence for functional cooperation of Ras-activated Ets transcriptions factors with the Vitamin D receptor in 1,25-dihydroxyvitamin D(3)-mediated induction. J. Biol. Chem. 275 1 (2000) 47-55
28. Albertson D.G., Yistra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., Kuo W.L., Gray J.W., and Pinkel D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 25 2 (2000) 144-146
29. Friedrich M., Rafi L., Mitschele J., Tilgen W., Schmidt W., and Reichrath J. Analysis of the Vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 164 (2003) 239-246
30. Bertone-Johnson E.R., Chen W.Y., Holick M.F., Hollis B.W., Colditz G.A., Willett W.C., and Hankinson S.E. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 14 8 (2005) 1991-1997
31. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., and Colston K.W. Plasma 25-hydroxy vitamin D concentrations, Vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur. J. Cancer 41 8 (2005) 1164-1169
32. Chen W.Y., Bertone-Johnson E.R., Hunter D.J., Willett W.C., and Hankinson S.E. Association between polymorphisms in the Vitamin D receptor and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 14 10 (2005) 2335-2339
33. Nagai M.A., Barbosa H.S., Zago M.A., Araujo W.J.A., Nishimoto I.N., Salaorni S., Costa L.N.G., Araujo M.S., Oliveira A.G.C., Mourao Neto M., and Brentani M.M. TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int. J. Oncol. 23 1 (2003) 189-196
34. Saraiva G.L., Cendoroglo M.S., Ramos L.R., Araujo L.M.Q., Vieira J.G.H., Kunii I., Hayashi L.F., Correa M.P., and Castro M.L. Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of São Paulo (23°34′S), Brazil. Osteoporos Int. 16 12 (2005) 1649-1654
35. Hiatt R.A., Krieger N., Lobaugh B., Drezner M.K., Vogelman J.H., and Orentreich N. Prediagnostic serum Vitamin D and breast cancer. J. Natl. Cancer Inst. 90 6 (1998) 461-463
36. Welsh J., Wietzke J.A., Zinser G.M., Byrne B., Smith K., and Narvaez C.J. Vitamin D-3 receptor as a target for breast cancer prevention. J. Nutr. 133 Suppl. 7 (2003) 2425S-2433S
37. Hewison M., Zehnder D., Bland R., and Stewart P.M. 1α-Hydroxylase and the action of Vitamin D. J. Mol. Endocrinol. 25 2 (2000) 141-148
38. 3-1α-hydroxilase in breast tissue. In: Norman A.W., Bouillon R., and Thomasset M. (Eds). Vitamin D Endocrine system (2000), University of California, Riverside 189-191
39. Sergersten U., Holm P.K., Bjorklund P., Hessman O., Nordgren H., Binderup L., Akerstrom G., Hellman P., and Westin G. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated Vitamin D analogue. Breast Cancer Res. 7 6 (2005) R980-R986
40. Townsend K., Banwell C.M., Guy M., Colston K.W., Mansi J.L., Stewart P.M., Campbell M.J., and Hewison M. Autocrine metabolism of vatamin D in normal and malignant breast tissue. Clin. Cancer Res. 11 9 (2005) 3579-3586
41. Anderson M.G., Nakane M., Ruan X., Kroeger P.E., and Wu-Wong J.R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 57 2 (2006) 234-240